News | News By Subject | News by Disease News By Date | Search News

Schizophrenia News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Braeburn Pharma Keeps Up with Competitors with Long-Acting Risperidone for Schizophrenia     5/17/2017
Minerva Neurosciences (NERV)'s Stock More than Tripled on Positive Phase II Schizophrenia Drug Data     5/27/2016
FDA Spurns Otsuka Pharma, Proteus Digital Health's Drug/Device Combo     4/27/2016
Arena (ARNA) Scores a $262 Million Schizophrenia Deal with Boehringer Ingelheim     1/13/2016
Neurocrine Biosciences (NBIX)'s NBI-98854 Hits Primary Enpoint in Phase III Study     10/9/2015
FDA Green Lights Alkermes (ALKS)' Schizophrenia Treatment Aristada     10/7/2015
FDA Approves Allergan (AGN) and Gedeon Richter (RIG2.F)'s Antipsychotic Vraylar     9/18/2015
Intra-Cellular Therapies Surges as Schizophrenia Drug Met Primary Endpoint in Phase III     9/17/2015
FORUM Pharma Halts Clinical Trials for Alzheimer’s and Schizophrenia Drug     9/17/2015
GW Pharma (GWPH) Surges on Positive Phase II Cannabis-Based Drug Study for Schizophrenia and Some Rare Diseases     9/16/2015
EXCLUSIVE: Moleculera Labs Will Add Close to A Dozen As It Doles Out $300K Grant     7/8/2015
In Hearings, University of Minnesota Admits Problems in Solvay Pharmaceuticals, Inc.’s Schizophrenia Drug     5/11/2015
Deaths Review of Eli Lilly (LLY)'s Antipsychotic Zyprexa Relprevv "Inconclusive"     3/25/2015
2015 Could Be Blockbuster Year for Alkermes plc (ALKS), Says Citi     12/17/2014
Pfizer (PFE)'s Antipsychotic Geodon Could Cause Fatal Skin Reaction: FDA     12/15/2014

News from Around the Web
First Blood Test To Accurately Diagnose Depression And Schizophrenia Developed, Yale Study Reveals     3/21/2017
Spotlight Hits This Little-Known Generic Biotech That Raised Price of Schizophrenia Drug by 1,650%     10/7/2016
How Artificial Intelligence Could Help Diagnose Mental Disorders, NeuroLex Diagnostics Reveals     9/2/2016
For Young People With Schizophrenia, Physical And Mental Exercises Offer Hope, UCLA Study     4/6/2016
Low Brain Levels of Vitamin B12 in Schizophrenics and Autistic Patients, Nova Southeastern University Researchers Reveal     1/25/2016
High Fat/Low Carb Diet Could Combat Schizophrenia, James Cook University Study     12/18/2015
Brain Scans Suggest Schizophrenia Is Not One Disease, Washington University in St. Louis Study Reveals     10/16/2015
Cannabis May Cause Schizophrenia, University of Calgary Researcher Warns     9/24/2015
Brain Scans May Help Schizophrenia Treatment, Zucker Hillside Hospital Study     9/17/2015
Retinal Changes Offer Clues About Brain Pathology Of Schizophrenia, Rutgers University Study     9/11/2015
Microbiomes Associated With Schizophrenia ID'd, George Washington University Study     8/26/2015
Can Fish Oil Slow Down Schizophrenia? University of Melbourne Study     8/13/2015
A Little Jolt Helps The Brain Get Back On Track, Vanderbilt University Study     7/9/2015
Presidential Candidate Mike Huckabee Uses Schizophrenia As A Slur, Gets It Wrong     7/7/2015
Does Creativity Share Genetic Roots With Schizophrenia? Maybe, King's College London Study     6/9/2015

Press Releases
Sunovion’s Latuda (Lurasidone HCI) Receives Health Canada Approval To Treat Adolescents With Schizophrenia     7/21/2017
Vanda (VNDA) Receives Negative Opinion For Marketing Authorization From The EMA On Fanaptum For The Treatment Of Schizophrenia     7/21/2017
IBM (IBM) And University of Alberta Publish New Data On Machine Learning Algorithms To Help Predict Schizophrenia     7/21/2017
Recordati: The European Commission (EC) Approves Reagila (Cariprazine) For The Treatment Of Schizophrenia     7/19/2017
Alkermes (ALKS) Slips As Weight Gain Concerns Sully Late-Stage Schizophrenia Data     6/30/2017
Minerva Neurosciences (NERV) Announces Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase III Trial For The Treatment Of Negative Symptoms In Patients With Schizophrenia     6/22/2017
Alkermes (ALKS) Release: FDA Approves Two-Month ARISTADA For Treatment Of Schizophrenia     6/6/2017
Minerva Biotechnologies Corporation Announces Outcome Of End-Of-Phase II Meeting With FDA     5/15/2017
Intra-Cellular Therapies (ITCI) Dropped To A New Low After the FDA Requests More Info On Schizophrenia Drug     5/2/2017
Alkermes (ALKS) Announces Completion Of Patient Enrollment In Pivotal Antipsychotic Efficacy Study Of ALKS 3831 For Schizophrenia     5/1/2017
Braeburn Pharma Achieves Primary Endpoint In Pivotal Phase II/III Study Of BB0817, Risperidone 6-Month Implant For Treatment Of Schizophrenia     4/27/2017
Newron Pharma (NWRN) Presents Encouraging Detailed Results Of Its Phase IIa Study With Evenamide In Patients With Schizophrenia     3/27/2017
Neurocrine Biosciences (NBIX) Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia     3/21/2017
First Blood Test To Accurately Diagnose Depression And Schizophrenia Developed, Yale Study Reveals     3/21/2017
Newron Pharma (NWRN) To Present At The 16th International Congress On Schizophrenia Research     3/16/2017

//-->